Review



ubc13 ube2n  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech ubc13 ube2n
    Ubc13 Ube2n, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/UBC13+Antibody/pm41771342-101-17-24
    Average 93 stars, based on 13 article reviews
    ubc13 ube2n - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Immunohistochemistry:

    Article Title: SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression
    Article Snippet: A total of 75 cases of human LUAD and 75 cases of para-carcinoma tissues were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA150CS03), and 92 cases of human LUAD and 88 cases of para-carcinoma tissues with overall survival rates were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA180Su04). .. The IHC staining and evaluation were performed as previously described [ ], using 1:100 dilution of an anti-UBE2N antibody (Proteintech, 10243-1-AP) and 1:200 dilution of an anti-SP1 antibody (Proteintech, 21962-1-AP). .. BEAS-2B, A549, H1299, and PC9 cell lines were purchased from the ATCC, cultured in RPMI1640 medium (Biological Industries) with 10% fetal bovine serum (Biological Industries) and 1% penicillin-streptomycin (Gibco Life Technologies) at 37 °C in 5% CO 2 .

    Article Title: SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression.
    Article Snippet: A total of 75 cases of human LUAD and 75 cases of paracarcinoma tissues were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA150CS03), and 92 cases of human LUAD and 88 cases of para-carcinoma tissues with overall survival rates were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA180Su04). .. The IHC staining and evaluation were performed as previously described [41], using 1:100 dilution of an anti-UBE2N antibody (Proteintech, 10243-1-AP) and 1:200 dilution of an anti-SP1 antibody (Proteintech, 21962-1-AP). .. BEAS-2B, A549, H1299, and PC9 cell lines were purchased from the ATCC, cultured in RPMI1640 medium (Biological Industries) with 10% fetal bovine serum (Biological Industries) and 1% penicillin-streptomycin (Gibco Life Technologies) at 37 °C in 5% CO2.

    Staining:

    Article Title: SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression
    Article Snippet: A total of 75 cases of human LUAD and 75 cases of para-carcinoma tissues were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA150CS03), and 92 cases of human LUAD and 88 cases of para-carcinoma tissues with overall survival rates were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA180Su04). .. The IHC staining and evaluation were performed as previously described [ ], using 1:100 dilution of an anti-UBE2N antibody (Proteintech, 10243-1-AP) and 1:200 dilution of an anti-SP1 antibody (Proteintech, 21962-1-AP). .. BEAS-2B, A549, H1299, and PC9 cell lines were purchased from the ATCC, cultured in RPMI1640 medium (Biological Industries) with 10% fetal bovine serum (Biological Industries) and 1% penicillin-streptomycin (Gibco Life Technologies) at 37 °C in 5% CO 2 .

    Article Title: SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression.
    Article Snippet: A total of 75 cases of human LUAD and 75 cases of paracarcinoma tissues were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA150CS03), and 92 cases of human LUAD and 88 cases of para-carcinoma tissues with overall survival rates were obtained from SHANGHAI OUTDO BIOTECH CO., LTD., China. (Cat No.: HLugA180Su04). .. The IHC staining and evaluation were performed as previously described [41], using 1:100 dilution of an anti-UBE2N antibody (Proteintech, 10243-1-AP) and 1:200 dilution of an anti-SP1 antibody (Proteintech, 21962-1-AP). .. BEAS-2B, A549, H1299, and PC9 cell lines were purchased from the ATCC, cultured in RPMI1640 medium (Biological Industries) with 10% fetal bovine serum (Biological Industries) and 1% penicillin-streptomycin (Gibco Life Technologies) at 37 °C in 5% CO2.

    Incubation:

    Article Title: UBE2N inhibition abrogates cancer chemoresistance and metastasis in lung adenocarcinoma.
    Article Snippet: Chemoresistance and metastasis remain significant challenges in cancer therapy, resulting in treatment failures for cancer patients.. Therefore, there is a need to investigate the mechanisms underlying cancer chemoresistance and metastasis, identify novel drug targets, and develop innovative antitumor medications.. In this study, we have shown that the ubiquitin conjugating enzyme UBE2N plays a crucial role in promoting chemoresistance and metastasis in lung adenocarcinoma (LUAD) both in vitro and in vivo.

    Western Blot:

    Article Title: SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression
    Article Snippet: .. Western blotting was performed as described previously [ ], using 1:1000 dilution of an anti-UBE2N antibody (Proteintech, 10243-1-AP), 1:1000 dilution of an anti-SP1 antibody (Proteintech, 21962-1-AP) and 1:1000 dilution of an anti-β actin antibody (Proteintech, 20536-1-AP). .. We annealed shRNAs for UBE2N and SP1 and cloned them into the pLV-H1-EF1α-puro vector (Biosettia).

    Article Title: SP1 transcriptionally regulates UBE2N expression to promote lung adenocarcinoma progression.
    Article Snippet: .. Western blotting was performed as described previously [42], using 1:1000 dilution of an anti-UBE2N antibody (Proteintech, 10243-1-AP), 1:1000 dilution of an anti-SP1 antibody (Proteintech, 21962-1-AP) and 1:1000 dilution of an anti-β actin antibody (Proteintech, 20536-1-AP). .. We annealed shRNAs for UBE2N and SP1 and cloned them into the pLV-H1-EF1α-puro vector (Biosettia).



    Similar Products

    ubc13 ube2n  (Proteintech)
    93
    Proteintech ubc13 ube2n
    Ubc13 Ube2n, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/UBC13+Antibody/pm41771342-101-17-24
    Average 93 stars, based on 1 article reviews
    ubc13 ube2n - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    ube2n  (Proteintech)
    93
    Proteintech ube2n
    Ube2n, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/UBC13+Antibody/pm41317936-155-1-9
    Average 93 stars, based on 1 article reviews
    ube2n - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti ubc13  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti ubc13
    Anti Ubc13, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/UBE2N%2FUbc13+Rabbit+mAb/pmc12583537-53-0-2
    Average 94 stars, based on 1 article reviews
    anti ubc13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    monoclonal antibodies against ube2n  (ABclonal Biotechnology)
    93
    ABclonal Biotechnology monoclonal antibodies against ube2n
    Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, <t>UBE2N</t> (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.
    Monoclonal Antibodies Against Ube2n, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/Ube2N+%2F+Ubc13+Rabbit+mAb/pmc12375651-79-0-8
    Average 93 stars, based on 1 article reviews
    monoclonal antibodies against ube2n - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti ube2n antibody  (Proteintech)
    93
    Proteintech anti ube2n antibody
    Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, <t>UBE2N</t> (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.
    Anti Ube2n Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/UBC13+Antibody/pm40544189-47-9-11
    Average 93 stars, based on 1 article reviews
    anti ube2n antibody - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    rabbit anti-ube2n  (Huabio Inc)
    90
    Huabio Inc rabbit anti-ube2n
    Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, <t>UBE2N</t> (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.
    Rabbit Anti Ube2n, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/rabbit+anti+ube2n/pm40349344-236-171-169
    Average 90 stars, based on 1 article reviews
    rabbit anti-ube2n - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    vinculin  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc vinculin
    Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, <t>UBE2N</t> (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.
    Vinculin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/UBE2N%2FUbc13+Antibody/pm40269158-1098-53-54
    Average 93 stars, based on 1 article reviews
    vinculin - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti ube2n  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti ube2n
    Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, <t>UBE2N</t> (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.
    Anti Ube2n, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/UBE2N%2FUbc13+Rabbit+mAb/pmc11894314-39-76-78
    Average 94 stars, based on 1 article reviews
    anti ube2n - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti ube2n invitrogen  (Thermo Fisher)
    86
    Thermo Fisher anti ube2n invitrogen
    Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, <t>UBE2N</t> (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.
    Anti Ube2n Invitrogen, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+ube2n+antibody/pm38977901-574-101-103
    Average 86 stars, based on 1 article reviews
    anti ube2n invitrogen - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, UBE2N (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: Screening of key prognostic genes in LUAD. (A) The Venn diagram for intersecting prognostic genes. (B) The Venn diagram for intersecting common prognostic genes and anti-viral genes. (C–E) Survival curves generated by stratifying patients based on the median expression levels of key genes, UBE2N (C) , USP44 (D) , and SENP7 (E) . (F) Differential expression of key genes in LUAD and paired paracancerous tissues.

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: Generated, Expressing, Quantitative Proteomics

    Validation of the prognostic roles of UBE2N and USP44 across multiple cohorts. (A, B) Survival curves were plotted by grouping patients according to UBE2N expression in the GSE3141 (A) and GSE50081 (B) cohorts. (C, D) Survival curves were plotted by grouping patients according to USP44 expression in the GSE19188 (C) and GSE50081 (D) cohorts. (E, F) DFS and RFS analyses based on UBE2N expression in the GSE30219 (E) and GSE31210 (F) cohorts. (G, H) DFS and RFS analyses based on USP44 expression in the GSE30219 (G) and GSE31210 (H) cohorts.

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: Validation of the prognostic roles of UBE2N and USP44 across multiple cohorts. (A, B) Survival curves were plotted by grouping patients according to UBE2N expression in the GSE3141 (A) and GSE50081 (B) cohorts. (C, D) Survival curves were plotted by grouping patients according to USP44 expression in the GSE19188 (C) and GSE50081 (D) cohorts. (E, F) DFS and RFS analyses based on UBE2N expression in the GSE30219 (E) and GSE31210 (F) cohorts. (G, H) DFS and RFS analyses based on USP44 expression in the GSE30219 (G) and GSE31210 (H) cohorts.

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: Biomarker Discovery, Expressing

    UBE2N was identified as an independent prognostic indicator of LUAD and correlates with clinicopathologic factors. (A, B) Prognostic independence analyses of key genes and clinicopathologic factors in TCGA-LUAD (A) and GSE30219 (B) cohorts. (C–J) Correlation between the expression of UBE2N and different clinicopathologic factors.

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: UBE2N was identified as an independent prognostic indicator of LUAD and correlates with clinicopathologic factors. (A, B) Prognostic independence analyses of key genes and clinicopathologic factors in TCGA-LUAD (A) and GSE30219 (B) cohorts. (C–J) Correlation between the expression of UBE2N and different clinicopathologic factors.

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: Expressing

    Validation of the association between UBE2N and the clinicopathological progression of LUAD in multiple cohorts. (A, B) Violin plots depict the correlation between UBE2N expression and clinical pathological parameters in cohorts GSE30219 (A) and GSE31210 (B) . (C) Expression levels of UBE2N in histologic grades with different degrees of differentiation in the GSE48465 dataset.

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: Validation of the association between UBE2N and the clinicopathological progression of LUAD in multiple cohorts. (A, B) Violin plots depict the correlation between UBE2N expression and clinical pathological parameters in cohorts GSE30219 (A) and GSE31210 (B) . (C) Expression levels of UBE2N in histologic grades with different degrees of differentiation in the GSE48465 dataset.

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: Biomarker Discovery, Expressing

    Investigation of the co-expressed gene network and associated functional pathways of UBE2N. (A) Heatmap showing the expression of co-expressed genes of UBE2N. (B) PPI network involving UBE2N and its co-expressed genes. (C) Volcano plot of UBE2N-related differential genes. (D) Functional enrichment analysis of UBE2N-related differential genes. (E, F) KEGG pathways enriched in high-UBE2N (E) and low-UBE2N groups (F) .

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: Investigation of the co-expressed gene network and associated functional pathways of UBE2N. (A) Heatmap showing the expression of co-expressed genes of UBE2N. (B) PPI network involving UBE2N and its co-expressed genes. (C) Volcano plot of UBE2N-related differential genes. (D) Functional enrichment analysis of UBE2N-related differential genes. (E, F) KEGG pathways enriched in high-UBE2N (E) and low-UBE2N groups (F) .

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: Functional Assay, Expressing

    UBE2N-related TME and immune functional phenotypes. (A) The violin plot of tumor-infiltrating immune cell abundance. (B) The violin plot of TME scores. (C) The box plot of tumor purity. (D–F) Box plots of the expression of inhibitory immunomodulatory genes (D) , stimulatory immunomodulatory genes (E) , and genes related to antigen presentation and processing (F) .

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: UBE2N-related TME and immune functional phenotypes. (A) The violin plot of tumor-infiltrating immune cell abundance. (B) The violin plot of TME scores. (C) The box plot of tumor purity. (D–F) Box plots of the expression of inhibitory immunomodulatory genes (D) , stimulatory immunomodulatory genes (E) , and genes related to antigen presentation and processing (F) .

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: Functional Assay, Expressing, Immunopeptidomics

    Role of UBE2N in tumor immune evasion and immunotherapy. (A–C) Publicly available CRISPR screen data reveal UBE2N as a promoter of tumor immune evasion. (D–F) Role of UBE2N expression in suggesting prognosis in cancer patients receiving immunotherapy. (G) IPS scores in UBE2N subgroups. (H) Role of UBE2N expression in predicting immunotherapy response in different cohorts.

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: Role of UBE2N in tumor immune evasion and immunotherapy. (A–C) Publicly available CRISPR screen data reveal UBE2N as a promoter of tumor immune evasion. (D–F) Role of UBE2N expression in suggesting prognosis in cancer patients receiving immunotherapy. (G) IPS scores in UBE2N subgroups. (H) Role of UBE2N expression in predicting immunotherapy response in different cohorts.

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: CRISPR, Expressing

    Role of UBE2N in cancer chemotherapy and targeted therapy. (A–L) Box plots of differences in drug sensitivity of patients in different UBE2N subgroups to chemotherapeutic and targeted agents including Docetaxel (A) , 5-Fluorouracil (B) , Cisplatin (C) , Cyclophosphamide (D) , MN-64 (E) , Selumetinib (F) , Ibrutinib (G) , Axitinib (H) , SB216763 (I) , Nelarabine (J) , Doramapimod (K) , and Ribociclib (L) . (M–O) Chemical structure diagrams of three potential compounds to inhibit UBE2N.

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: Role of UBE2N in cancer chemotherapy and targeted therapy. (A–L) Box plots of differences in drug sensitivity of patients in different UBE2N subgroups to chemotherapeutic and targeted agents including Docetaxel (A) , 5-Fluorouracil (B) , Cisplatin (C) , Cyclophosphamide (D) , MN-64 (E) , Selumetinib (F) , Ibrutinib (G) , Axitinib (H) , SB216763 (I) , Nelarabine (J) , Doramapimod (K) , and Ribociclib (L) . (M–O) Chemical structure diagrams of three potential compounds to inhibit UBE2N.

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques:

    Experimental validation of the expression profile and tumor biology of UBE2N. (A) IHC sections reveal high expression of UBE2N in LUAD tissues. (B) IHC sections reveal a correlation between UBE2N expression and tumor diameter. (C) Knockdown of UBE2N expression with siRNA. (D) CCK-8 assay to detect the effect of UBE2N on the proliferative viability of A549 cells. (E–G) Experimental detection of the impact of UBE2N on apoptosis in A549 cells.

    Journal: Frontiers in Immunology

    Article Title: UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1636503

    Figure Lengend Snippet: Experimental validation of the expression profile and tumor biology of UBE2N. (A) IHC sections reveal high expression of UBE2N in LUAD tissues. (B) IHC sections reveal a correlation between UBE2N expression and tumor diameter. (C) Knockdown of UBE2N expression with siRNA. (D) CCK-8 assay to detect the effect of UBE2N on the proliferative viability of A549 cells. (E–G) Experimental detection of the impact of UBE2N on apoptosis in A549 cells.

    Article Snippet: Monoclonal antibodies against UBE2N (A9257) were purchased from Abclonal (Wuhan, China).

    Techniques: Biomarker Discovery, Expressing, Knockdown, CCK-8 Assay